Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBVD Hexavalent Vaccine in Healthy Infants
NCT05457946Phase 3Completed
- Sponsor
- LG Chem
- Start
- Jul 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lomustine + bleomycin + vinblastine + doxorubicin in diphtheria, Tetanus, pertussis and 3 more (4 arms), sponsored by LG Chem. Primary endpoint: Seroprotection/seroconversion/vaccine-response rate. Started Jul 2018; status: completed.
02
Drugs
lomustine + bleomycin + vinblastine + doxorubicin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT05457946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457946.